Akademik Veri Yönetim Sistemi
World Journal of Oncology, cilt.15, sa.4, 2024 (ESCI)
Background: The aim of the study was to evaluate the efficacy of ste
reotactic body radiotherapy (SBRT) using the CyberKnife-M6 (CK
M6) with lung optimized treatment (LOT) module in patients with
primary lung cancer and lung metastases.
Methods: Forty-two lesions from 35 patients were treated between
2019 and 2022. Four-dimensional computed tomography images
were obtained when the patients were in a free breathing modality.
Tracking modality was selected prospectively according to the vis
ibility of the target. The median prescribed dose was 48 Gy in four
fractions (fx) (28 - 55 Gy/1- 7 fx). The median age was 68 years (47 -
82 years), and 43% of cases were adenocarcinoma. The median lesion
size was 15 mm (6 - 36 mm).
Results: Complete, partial and stable responses were obtained as
26%, 62%, and 9.5% at a median of 2 months (1 - 6 months), and
35.5%, 47.5% and 5% at the 12th month evaluation, respectively.
Grade 3 and higher toxicity was not observed in any case. The mean
and 2-year overall survival (OS) was 31.5 months and 54%, and the
local recurrence-free survival (LRFS) was 29.6 months and 51%,
respectively. In univariate analysis, target lesion type, complete re
sponse (CR), and higher esophagus maximum dose were favorable
factors for OS and LRFS (P < 0.05). The CR at 12th month evaluation
remained significant in multivariate analysis in terms of OS (hazard
ratio = 8.602, 95% confidence interval: 1.05 - 70.01; P = 0.044).
Conclusions: A mean LRFS of 29.6 months and OS of 31.5 months
were obtained in patients with primary and metastatic lung cancer.
With a median treatment time of 25 min, motion-managed strategy with CK-M6-LOT-based SBRT is an effective, safe, and comfortable
treatment method for lung cancer.